A pioneer in precision

World leading innovation

Pioneering Precision Antimicrobials | Combating Drug-Resistant Pathogens | Innovation in Human and Animal Health

ZymIQ Biopharma leads the fight against antimicrobial resistance with enzyme-based and phage-derived solutions. It was formed through the acquisition of Novalysin AB and Delmont Laboratories. ZymIQ Biopharma blends expertise in phage science with advanced research in enzyme-based antibiotics. Key projects like Staphage Lysate (SPL)® and a novel tuberculosis project target global health challenges. Focused on precision antimicrobials, ZymIQ Biopharma aims to revolutionize treatment for human and animal health with targeted, effective, and safe therapies.

Key Projects and Achievements

Staphage Lysate (SPL)®

A novel phage-derived therapy for staphylococcal infections, transitioning from human to veterinary use, with plans for reintroduction in human medicine.

Tuberculosis

Development of an innovative enzyme-based antibiotic platform targeting drug-resistant Mycobacterium strains. Our approach is designed to improve specificity, reduce treatment time, and combat multi-drug-resistant strains of tuberculosis.